金斯瑞生物科技(01548.HK):Smarter cost balance

发布于: 新闻转发:0回复:3喜欢:4
机构:国信证券 评级:BUY 目标价:HKD36.20 FY17 Result beat on smaller opex to sales. Genscript reported FY17 net profit at USD26m, flat growth y-o-y. Core profits after exchange gain/loss and other one-off items, came in USD35m, climbed 52% ... 网页链接

全部讨论

2018-03-21 20:14

前途一片光明

文盲看不懂 是几年后的价位吗

2018-03-21 14:14

嗯嗯,有道理,说的好